• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 18-75 at time of enrollment

• Diagnosis of Chronic Pancreatitis episode is not attributable to gallstones (i.e. suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis.

• Ability to take oral medication and be willing to adhere to the dosing regimen

• Normal Calcium levels- 8.5 to 10.2 mg/dL

• Normal Phosphate levels- 2.8 to 4.5 mg/dL

• Normal Parathyroid hormone levels- 10 to 65 pg/mL

• For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 1 week after the end of Investigational Product administration

• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner

• No prior pancreatic surgery

• Pancreatic necrosis, if present, is \<50% (to be verified by radiologist)

• No involvement in any interventional trials currently or within 6 months of enrollment